This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here
HOME / ELIQUIS® (APIXABAN) DOSING INFORMATION ELIQUIS IRELAND / QUICK REFERENCE DOSING GUIDE
ELIQUIS® (apixaban) Quick Reference Dosing Guide
ELIQUIS for the treatment of NVAF / DVT / PE
Download the ELIQUIS Dosing Card here
This download is only intended for Healthcare Professionals in Ireland, it provides a summary of the above dosing information.
This Dosing Card may be read in its electronic form (PDF) or it may be printed and read.
If the Dosing Card is printed, please ensure that:
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
BD = Twice Daily DOAC = Direct-acting Oral Anticoagulant INR = International Normalised Ratio SmPC = Summary of Product Characteristics UFH = Unfractionated Heparin
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Alexander JH et al. JAMA Cardiol 2016; 1: 673-681.
- Agnelli G et al. N Engl J Med 2013; 369: 799-808
- Steffel J et al. Eur Heart J 2018; 39: 1330–1393.
Date of Preparation: September 2025 | Job Description: 432-IE-2500027